Patient info Open main menu

Rhokiinsa 200 micrograms / M eye drops – patient leaflet, side effects, dosage

Text from the MHRA, as of · About this document

Medicine strength:
200 micrograms
Contains active substance:
ATC code:

Patient leaflet - Rhokiinsa 200 micrograms / M eye drops

1. What Rhokiinsa is and what it is used for

Rhokiinsa contains an active substance called netarsudil. Netarsudil belongs to a group of medicines called

“Rho kinase inhibitors”, which work to reduce the amount of fluid inside the eye and so lower its pressure. Rhokiinsa is used to lower pressure in the eyes in adults who have an eye condition known as glaucoma or who have raised pressure in their eyes. If the pressure in the eye is too high, it can damage your sight.

2. What you need to know before you use Rhokiinsa

Do not use Rhokiinsa:

  • if you are allergic to netarsudil or

    any of the other ingredients of this medicine (listed in section 6). Warnings and precautions

    • Do not use Rhokiinsa more than

      once a day, as you may experience more side effects.

    • Tell your doctor if you experience

      decreased vision or eye pain during treatment with this medicine. This might be due to a type of swelling of the clear outer layer of the eye (reticular epithelial corneal oedema). This effect has been reported following administration of this medicine to the eye in patients with certain risk factors, including previous surgery to the eye. It usually improves following discontinuation of the medicine. Children and adolescents

Rhokiinsa should not be used in children and teenagers under 18 years of age as it has only been studied in adults. Other medicines and Rhokiinsa

Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines (see section 3 ‘How to use Rhokiinsa’).

Pregnancy and breast-feeding

If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Do not use Rhokiinsa if you are pregnant or breastfeeding unless your doctor still recommends it.

Driving and using machines

Rhokiinsa has negligible influence on the ability to drive and use machines. You may find that your vision is blurred or abnormal just after using Rhokiinsa. Do not drive or use machines until the symptoms are cleared.

Rhokiinsa contains benzalkonium chloride

This medicine contains approximately 150 micrograms benzalkonium chloride in each ml of solution.

Benzalkonium chloride may be absorbed by soft contact lenses and may change the colour of the contact lenses. You should remove contact lenses before using this medicine and put them back 15 minutes afterwards (see section 3 ‘How to use Rhokiinsa’). Benzalkonium chloride may also cause eye irritation, especially if you have dry eyes or disorders of the cornea (the clear layer at the front of the eye). If you feel abnormal eye sensation, stinging or pain in the eye after using this medicine, talk to your doctor.

3. How to use Rhokiinsa

Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

Only use Rhokiinsa for your eyes (ocular use). Do not swallow or inject.

The recommended dose is one drop in the affected eye or eyes once a day in the evening. Use the medicine at around the same time each day.

Do not use more than one drop in the affected eye(s) once a day.

How to use

  • Wash your hands before you start.

    Contact lenses should be removed prior to instillation of Rhokiinsa (see section 2 ‘Rhokiinsa contains benzalkonium chloride’).

  • Do not touch the dropper with your fingers when opening or closing the bottle. It could contaminate the drops.
  • Twist off the bottle cap, and lie the cap on a clean surface on its side. Continue to hold the bottle, ensuring that the tip doesn’t come into contact with anything.
  • Hold the bottle, pointing down,

    between your thumb and fingers.

  • Tilt your head back.
  • Pull down your lower eyelid with a clean finger to form a ‘pocket’ between the eyelid and your eye. The drop will go in here (Picture 1).
  • Bring the bottle tip close to the eye.

    Do this in front of a mirror if it helps.

  • Do not touch your eye, eyelid,

    surrounding areas or other surfaces with the dropper. It could contaminate the drops.

  • Gently squeeze the bottle to release one drop of Rhokiinsa into your eye.
  • Only put one drop into your eye each time. If a drop misses your eye, try again.
  • If you need to use the drops in both eyes, repeat the steps for your other eye while you have the bottle open.
  • Put back the bottle cap to close the bottle.

If you are using other eye drops, wait at least five minutes after using them and then use Rhokiinsa last due to netarsudil’s vasodilating properties. If you are using eye ointments, these should be used last.

If you use more Rhokiinsa than you should

Rinse your eye with warm water. Do not put in any more drops until it is time for your next regular dose.

If you forget to use Rhokiinsa

Continue with the next dose as planned. Do not use a double dose to make up for a forgotten dose.

If you stop using Rhokiinsa

Do not stop using Rhokiinsa without first speaking to your doctor. If you stop using Rhokiinsa the pressure in your eye will not be controlled which could lead to loss of sight. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

The following non-serious side effects have been observed with Rhokiinsa: Very common side effects (may affect more than 1 in 10 people)

  • Effects in the eye:

    Eye redness; fine deposits on the front of the eye (corneal verticillata) Pain where the drops have been put in Common side effects (may affect up to 1 in 10 people)

  • Effects in the eye:

    Infection or inflammation of the eye; dryness of the eye or small breaks in the film of liquid on the surface of the eye (conjunctivitis, punctate keratitis); eye inflammation caused by an allergic reaction or prominent blood vessels; Eye discharge; eyes can become watery;

    Eye pain; feeling of grittiness or having something in the eye; general eye redness shortly after drops are put in; spots or patches of eye redness; Itchy eyelids; swelling around the eye; Clouding of the eye and vision may decrease somewhat; sensitive to light; blurred vision

  • General side effects: Headache Uncommon side effects (may affect up to 1 in 100 people)
  • Effects in the eye:

    Increased fluid pressure inside the eye; Inflammation of the coloured part of the eye (the iris); bulging of iris; small colored spots on the eye surface; Growth of eyelashes; loss of eyelashes (madarosis);

    Eyelid dryness; abnormal turning outward of the lower eyelid; eye dryness caused by inflammation of the glands of the eyelids; eyelid crusting; Eye disease related to diabetes (diabetic retinopathy);

    Excess folds of the conjunctiva (conjunctivochalasis);

    Blindness; blurred, double and halo vision; cataracts;

    Eye allergy;

    Glassy eyes; tiredness

  • General side effects:

    Increased allergic symptoms; Dizziness;

    Nasal discomfort and pain;

  • Effects on the skin: redness or itching

    of the skin; rash on skin; inflammation of the cartilage; picking of the skin Not known side effects (cannot be estimated from the available data)

  • Effects in the eye:

    Swelling of the clear outer layer of the

    eye (reticular epithelial corneal oedema)

    Reporting of side effects

    If you get any side effects, talk to your doctor, or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme: Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Rhokiinsa

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and bottle label after “EXP”. The expiry date refers to the last day of that month. Unopened bottles: Store in a refrigerator (2°C - 8°C).

After opening the bottle: Do not store above 25°C.

Do not use the bottle 4 weeks after first opening to prevent infections and use a new bottle.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Rhokiinsa contains

  • The active substance is netarsudil.

    Each ml of solution contains 200 micrograms netarsudil (as mesylate).

  • The other excipients are benzalkonium chloride (see section 2 under ‘Rhokiinsa contains benzalkonium chloride’), mannitol, boric acid, sodium hydroxide (for pH adjustment) and water for injections.

What Rhokiinsa looks like and contents of the pack

Rhokiinsa 200 micrograms/ml eye drops, solution (eye drops) is a clear, liquid eye drop solution in a plastic bottle. Each bottle contains 2.5 ml of the medicine and each pack contains one bottle with a screw-cap. Marketing Authorisation Holder

Santen Oy

Niittyhaankatu 20,

33720 Tampere,

Finland

Manufacturer

Santen Oy,

Kelloportinkatu 1,

33100 Tampere,

Finland

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder: United Kingdom

Santen UK Limited

Tel: +44 (0) 345 075 4863

This leaflet was last revised in 08/2025. Other sources of information

Detailed information on this medicine is available on the Medicines & Healthcare products Regulatory Agency (MHRA) website: www.mhra.gov.uk.

144 mm.

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PLGB 16058/0033

MHRA data as of 13 October 2026

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Rhokiinsa 200 micrograms / M eye drops

Active substance Netarsudil
Strength 200 micrograms
Pharmaceutical form Clear solution, pH 5 (approximately).
Excipients Benzalkonium chloride, Mannitol, Boric acid, Sodium hydroxide (for pH-adjustment), Water for injections
Shelf life 3 years
Opened bottle: 4 weeks after first opening the bottle. Do not store above 25°C.
Storage Store in a refrigerator (2°C – 8°C) until opened.
For storage conditions after first opening of the medicinal product, see section 6.3.
Drug group (ATC) Ophthalmologicals, antiglaucoma preparations and miotics
  1. S Sensory organ drugs
    1. S01 Ophthalmologicals
      1. S01E Antiglaucoma preparations and miotics
        1. S01EX Other antiglaucoma preparations
          1. S01EX05 netarsudil
Marketing authorisation PLGB 16058/0033 (first authorised 18 December 2024)
Marketing authorisation holder Santen Oy

Sources: the MHRA product information (products.mhra.gov.uk). Contains public sector information licensed under the Open Government Licence v3.0.